Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the NLRP3 inflammasome in cardiovascular diseases
Stefano Toldo, Eleonora Mezzaroma, Leo F. Buckley, et al.
Pharmacology & Therapeutics (2021) Vol. 236, pp. 108053-108053
Open Access | Times Cited: 179

Showing 1-25 of 179 citing articles:

Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology
Dobromir Dobrev, Jordi Heijman, Roddy Hiram, et al.
Nature Reviews Cardiology (2022) Vol. 20, Iss. 3, pp. 145-167
Open Access | Times Cited: 141
Role of inflammation, immunity, and oxidative stress in hypertension: New insights and potential therapeutic targets
Zenglei Zhang, Lin Zhao, Xingyu Zhou, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 140
Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions
Jun Ma, Yanan Li, Xiangyu Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 98
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
Nicola Potere, Marco Giuseppe Del Buono, Roberto Caricchio, et al.
EBioMedicine (2022) Vol. 85, pp. 104299-104299
Open Access | Times Cited: 78
The NLRP3 inflammasome in depression: Potential mechanisms and therapies
Cong‐Yuan Xia, Yuxuan Guo, Wenwen Lian, et al.
Pharmacological Research (2022) Vol. 187, pp. 106625-106625
Open Access | Times Cited: 73
Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
Runkai Chen, Hongrui Zhang, Botao Tang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 32
SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells
Alicia Villacampa, Enrique Alfaro, Cristina Morales, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Vascular endothelial cell injury: causes, molecular mechanisms, and treatments
Tian Xia, Jiachi Yu, Meng Du, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access | Times Cited: 1
Systemic and ovarian inflammation in women with polycystic ovary syndrome
Yi Zhai, Yanli Pang
Journal of Reproductive Immunology (2022) Vol. 151, pp. 103628-103628
Closed Access | Times Cited: 57
NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis
Nicola Potere, Evan C. Garrad, Yogendra Kanthi, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 11, pp. 2046-2060
Open Access | Times Cited: 30
Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism
Nicola Potere, Antonio Abbate, Yogendra Kanthi, et al.
JACC Basic to Translational Science (2023) Vol. 8, Iss. 9, pp. 1245-1261
Open Access | Times Cited: 29
Inhibitors of NLRP3 Inflammasome in Ischemic Heart Disease: Focus on Functional and Redox Aspects
Pasquale Pagliaro, Cláudia Penna
Antioxidants (2023) Vol. 12, Iss. 7, pp. 1396-1396
Open Access | Times Cited: 24
Pharmacological Cardioprotection against Ischemia Reperfusion Injury—The Search for a Clinical Effective Therapy
Qian Wang, Coert J. Zuurbier, Ragnar Huhn, et al.
Cells (2023) Vol. 12, Iss. 10, pp. 1432-1432
Open Access | Times Cited: 21
Atrazine exposure promotes cardiomyocyte pyroptosis to exacerbate cardiotoxicity by activating NF-κB pathway
Xuyan Zhao, Huan Luo, Sai Yao, et al.
The Science of The Total Environment (2024) Vol. 915, pp. 170028-170028
Closed Access | Times Cited: 9
The research progression of direct NLRP3 inhibitors to treat inflammatory disorders
Xiu Chen, Ping Zhang, Yu Zhang, et al.
Cellular Immunology (2024) Vol. 397-398, pp. 104810-104810
Closed Access | Times Cited: 8
Irisin improves diabetic cardiomyopathy-induced cardiac remodeling by regulating GSDMD-mediated pyroptosis through MITOL/STING signaling
Linhe Lu, Yalan Shao, Xiang Yuan Xiong, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116007-116007
Open Access | Times Cited: 7
Bazi Bushen capsule improves the deterioration of the intestinal barrier function by inhibiting NLRP3 inflammasome-mediated pyroptosis through microbiota-gut-brain axis
Shi-Xiong Zhang, Mengnan Li, Liping Chang, et al.
Frontiers in Microbiology (2024) Vol. 14
Open Access | Times Cited: 7
The critical role of short-chain fatty acids in health and disease: A subtle focus on cardiovascular disease-NLRP3 inflammasome-angiogenesis axis
Yao Juan, Yu Chen, Ming Xu
Clinical Immunology (2022) Vol. 238, pp. 109013-109013
Closed Access | Times Cited: 36
NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes.
Debashis Dutta, Jianuo Liu, Huangui Xiong
PubMed (2022) Vol. 14, Iss. 3, pp. 138-160
Closed Access | Times Cited: 32
Emerging Roles of Inflammasomes in Cardiovascular Diseases
Yingnan Liao, Kui Liu, Liyuan Zhu
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 30
Pyroptosis in cardiovascular diseases: Pumping gasdermin on the fire
Timur O. Yarovinsky, Meiling Su, Chaofei Chen, et al.
Seminars in Immunology (2023) Vol. 69, pp. 101809-101809
Open Access | Times Cited: 19
Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation
Simone Gastaldi, Carmine Rocca, Eleonora Gianquinto, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115542-115542
Open Access | Times Cited: 18
Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation
Jiaxin Hu, Jiamin Xu, Xi Tan, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023)
Open Access | Times Cited: 17
Mechanisms of NLRP3 inflammasome activation and the development of peptide inhibitors
Ye Tao, Weiyan Tao, Xiaoyi Chen, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 74, pp. 1-13
Closed Access | Times Cited: 16
NLRP3 deficiency protects against acetaminophen‑induced liver injury by inhibiting hepatocyte pyroptosis
Xinying Yuan, Peng Chen, Xiaoyu Luan, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 4
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top